Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA-LP Vaccines for Recurrent/Progressive Medulloblastoma
NCT07492316Phase 1Active, not recruiting
- Sponsor
- University of Florida
- Start
- Apr 2026
- Primary completion
- Sep 2030
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RNA-LP vaccine in medulloblastoma, sponsored by University of Florida. Primary endpoints: Manufacturing feasibility at 15 weeks, Safety of RNA-LP vaccine and 1 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
RNA-LP vaccine
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT07492316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492316.